165 related articles for article (PubMed ID: 22713937)
1. Dissolution rate enhancement of piroxicam by ordered mixing.
Saharan VA; Choudhury PK
Pak J Pharm Sci; 2012 Jul; 25(3):521-33. PubMed ID: 22713937
[TBL] [Abstract][Full Text] [Related]
2. Dissolution rate enhancement of gliclazide by ordered mixing.
Saharan VA; Choudhury PK
Acta Pharm; 2011 Sep; 61(3):323-34. PubMed ID: 21945911
[TBL] [Abstract][Full Text] [Related]
3. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol.
Karataş A; Yüksel N; Baykara T
Farmaco; 2005 Sep; 60(9):777-82. PubMed ID: 16084514
[TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
5. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
6. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
7. Immediate release of poorly soluble drugs from starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; Remon JP; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2007 Nov; 67(3):715-24. PubMed ID: 17537625
[TBL] [Abstract][Full Text] [Related]
8. The dissolution enhancement of piroxicam in its physical mixtures and solid dispersion formulations using gluconolactone and glucosamine hydrochloride as potential carriers.
Al-Hamidi H; Obeidat WM; Nokhodchi A
Pharm Dev Technol; 2015 Jan; 20(1):74-83. PubMed ID: 24392858
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the dissolution of indomethacin in interactive mixtures using added fine lactose.
Allahham A; Stewart PJ
Eur J Pharm Biopharm; 2007 Nov; 67(3):732-42. PubMed ID: 17540551
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement.
Sanganwar GP; Sathigari S; Babu RJ; Gupta RB
Eur J Pharm Sci; 2010 Jan; 39(1-3):164-74. PubMed ID: 19961931
[TBL] [Abstract][Full Text] [Related]
11. Soluble filler as a dissolution profile modulator for slightly soluble drugs in matrix tablets.
Dvorácková K; Rabisková M; Masteiková R; Muselík J; Krejcová K
Drug Dev Ind Pharm; 2009 Aug; 35(8):930-40. PubMed ID: 19274510
[TBL] [Abstract][Full Text] [Related]
12. Hydroxypropyl methylcellulose microspheres with piroxicam and piroxicam-hydroxypropyl-beta-cyclodextrin inclusion complex.
Jug M; Bećirević-Laćan M; Cetina-Cizmek B; Horvat M
Pharmazie; 2004 Sep; 59(9):686-91. PubMed ID: 15497750
[TBL] [Abstract][Full Text] [Related]
13. Counter-intuitive enhancement in the dissolution of indomethacin with the incorporation of cohesive poorly water-soluble inorganic salt additives.
Tay T; Allahham A; Morton DA; Stewart PJ
Eur J Pharm Biopharm; 2011 Nov; 79(3):674-82. PubMed ID: 21703348
[TBL] [Abstract][Full Text] [Related]
14. Evaluation and enhancement of physical stability of semi-solid dispersions containing piroxicam into hard gelatin capsules.
Karataş A; Bekmezci S
Acta Pol Pharm; 2013; 70(5):883-97. PubMed ID: 24147368
[TBL] [Abstract][Full Text] [Related]
15. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
[TBL] [Abstract][Full Text] [Related]
16. Sugar coated ceramic nanocarriers for the oral delivery of hydrophobic drugs: formulation, optimization and evaluation.
Kommineni S; Ahmad S; Vengala P; Subramanyam CV
Drug Dev Ind Pharm; 2012 May; 38(5):577-86. PubMed ID: 21961937
[TBL] [Abstract][Full Text] [Related]
17. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of dissolution rate of piroxicam using liquisolid compacts.
Javadzadeh Y; Siahi-Shadbad MR; Barzegar-Jalali M; Nokhodchi A
Farmaco; 2005 Apr; 60(4):361-5. PubMed ID: 15848213
[TBL] [Abstract][Full Text] [Related]
19. Effect of glucosamine HCl on dissolution and solid state behaviours of piroxicam upon milling.
Al-Hamidi H; Edwards AA; Douroumis D; Asare-Addo K; Nayebi AM; Reyhani-Rad S; Mahmoudi J; Nokhodchi A
Colloids Surf B Biointerfaces; 2013 Mar; 103():189-99. PubMed ID: 23201737
[TBL] [Abstract][Full Text] [Related]
20. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam.
Xuan JJ; Balakrishnan P; Oh DH; Yeo WH; Park SM; Yong CS; Choi HG
Int J Pharm; 2010 Aug; 395(1-2):317-23. PubMed ID: 20573569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]